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CHAPTER 1: Introduction
1.1 Cardiovascular Disease
Cardiovascular disease (CVD) is one of the most common causes of morbidity and
mortality worldwide. Its incidence is increasing globally as western lifestyles are adopted and
populations age.[1] The World Health Organization (WHO) has predicted an increase in
prevalence of CVD, with projected combined death toll of 24 million by 2030.
An increased blood cholesterol level, which is governed by cholesterol absorption,
synthesis, storage, and excretion, is one of the major risk factors leading to the development of
CVD.[2] It is a disease of the vascular intima, in which all of the vascular system from the aorta
to coronary arteries can be involved and is characterized by intimal plaques.[3] Currently, it is a
common disease in which fatty deposits called atheromatous plaques appear in the inner layers of
arteries.[3] The process is characterized, in its earliest stages, by perturbations in endothelial
function. Atherosclerosis is likely initiated when endothelial cells over express adhesion
molecules in response to turbulent flow in the setting of an unfavorable blood lipid profile.
Increased cellular adhesion and the associated endothelial dysfunction then “sets the stage” for
the recruitment of inflammatory cells, release of cytokines and recruitment of lipid into the
plaque.[4]
Proinflammatory biomarkers, shear stress and apolipoprotein-B sub-endothelial
accumulation in the artery wall have a significant contribution to atherosclerosis development.
Among these factors, cholesterol plays a major role in CVD.[5] Formation of plaques starts with
the deposition of small cholesterol crystals in the intima and its underlying smooth muscle. Then
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the plaques grow with the proliferation of fibrous tissues and the surrounding smooth muscle and
bulge inside the arteries and consequently reduce the blood flow. Connective tissue production
by fibroblasts and deposition of calcium in the lesion cause sclerosis or hardening of the arteries.
Finally, the uneven surface of the arteries results in clot formation and thrombosis, which leads
to the sudden obstruction of blood flow.[3] The cholesterol and fatty acid burden to the
atherosclerotic plaques, contribute to the formation and rupture of these plaques.[5]

1.1.1 Hyperlipidemia:
Hyperlipidaemia, or more accurately dyslipidaemia, is a major risk factor for CVD and
may account for up to 55% of age and gender-independent risk. The dyslipidaemia component
that accounts for the epidemiological risk is the ratio of total cholesterol to high density
lipoprotein-cholesterol (HDL-C), or alternatively the ratio of apolipoprotein B: A-1
concentrations, which identifies the fraction of lipid particles depositing cholesterol in the
vascular wall compared to those removing it. At its simplest, this process can be expressed as
non-HDL-C (difference of total and HDL-C) vs HDL-C.[1]
Atherosclerotic lesions contain large amounts of cholesterol, cholesteryl esters, and
cholesterol crystals. It is well established that high blood cholesterol levels are linked to the
pathogenesis of atherosclerosis. Furthermore, atherosclerosis-like vascular lesions can be
experimentally induced in animals fed a high-cholesterol diet. On the contrary, lowering levels
of serum cholesterol slows down atherogenesis, which can cause plaque regression and reduces
the overall risk of cardiovascular events. In addition to excessive amounts of lipids,
atherosclerotic lesions harbor all classes of immune cells and serum levels of acute-phase
reactants and inflammatory mediators which are linked to the risk of coronary heart disease.[6]
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The plasma level of cholesterol is determined by genetic factors, by the type and amount
of fat in the diet, and by other factors such as obesity, physical activity, and disease states. Based
on the results of animal studies, epidemiologic data, and interventional studies, there is good
evidence for an association between hypercholesterolemia and CVD. The association between
serum cholesterol levels and the risk of coronary heart disease is continuous. Familial
hypercholesterolemia, a disorder caused by an absent or defective LDL receptor, causes
premature coronary heart disease. Reduced levels of HDL cholesterol are associated with an
increased risk of coronary heart disease. Both the cholesterol level and the prevalence of
coronary heart disease are influenced by environmental factors, including diet. The evidence that
decreasing serum cholesterol levels with cholesterol-lowering drugs or dietary modification
slows or reverses the progression of coronary atherosclerosis and reduces coronary events comes
from many randomized trials that include more than 40,000 subjects. Lowering the cholesterol
level with diet or drug therapy also slows the progression of angiographically documented
coronary atherosclerosis in patients with arterial bypass grafts.[4] Hyperlipidemia and
hyperglycemia are related to increased oxidative damage, which affects antioxidant status and
lipoprotein levels. Studies have shown that lipid lowering medicinal herbs can reduce the blood
lipids especially after meals in addition to their antioxidant effects. Therefore, they can prevent
atherosclerosis and vascular endothelium damage.[3] Modifying several risk factors, such as
lowering the serum cholesterol level, the blood pressure, and the levels of LDL cholesterol and
by cessation of smoking, reduces the risk of ischemic heart disease. Individuals with several risk
factors benefit most from these measures. [4]
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1.1.2 Genetics:
Apolipoprotein A-I is the major protein constituent of human high density lipoproteins
(HDLs), which play a key role in reverse cholesterol transport (RCT), shuttling excess of
cholesterol from the circulation to the liver for catabolism. Even though only 5% of the total
circulating apoA-I is found in lipid-free or lipid-poor forms, it is thought that the highly dynamic
catabolism of HDL yields this protein conformation which subsequently acquires lipids,
enhancing cholesterol removal.[7]
Serum levels of HDL and its major protein apoAI are associated with decreased coronary
heart disease (CHD) rates . Anti-atherogenic properties of HDL and apoAI are attributed to their
reverse cholesterol transport capacity and anti-inflammatory effects. HDL and apoAI drive
cholesterol efflux from peripheral cells in general and macrophages in particular, thus preventing
foam cell formation and reducing inflammation. Reduced capacity to efflux cholesterol from
macrophages by HDL in serum is a predictor for atherosclerosis in mice and humans. ApoA1 is
critical for the unloading of cholesterol from macrophages, with pathologic and clinical
consequences like atherosclerosis. Both endogenous and exogenous apoAI were shown to
stimulate the secretion of macrophage apoE, another physiologic driver of cholesterol efflux.
Removal of cholesterol from the aortic wall was mediated through increasing local apoAI
concentration and upregulation of cellular cholesterol transporters. Lipid-free apoAI, HDLbound apoAI, and apoE act in synergy to extract cholesterol from macrophages, thus influencing
macrophage cholesterol accumulation, a hallmark of CVD.[8]

1.1.3 Oxidation:
Oxidative stress is defined as the presence of active oxygen species in excess of the
available antioxidant buffering capacity. Oxidative stress is well known to be involved in the
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pathogenesis

of

lifestyle-related

diseases,

including

hypertension,

diabetes

mellitus,

atherosclerosis, ischemic diseases, malignancies, or Alzheimer disease, Parkinson’s disease, and
amyotrophic lateral sclerosis.[9] Oxidative stress has been identified as critical in most of the key
steps in the pathophysiology of atherosclerosis and acute thrombotic events, including
dyslipidemia leading to atheroma formation, the oxidation of LDL, endothelial dysfunction,
plaque rupture, myocardial ischemic injury, and recurrent thrombosis. The role of oxidative
stress in the connection between the various coronary disease risk factors such as elevated blood
pressure, diabetes and cigarette smoking, and the clinical sequelae of disease associated with
vasoconstriction, thrombosis, plaque rupture, and vascular remodeling has been recognized by
Moreno and Fuster. Oxidative stress has been implicated as well in diabetic cardiomyopathy,
congestive cardiomyopathy, and hypertensive heart disease. Pathological inflammation, a
complex whole-cellular pathway, is a cascade that begins with the production of excess free
radicals that frequently arise from mitochondria responding to internal or environmental stress
and that trigger several signaling steps that endup producing the substances that actually cause
the classical signs of redness, swelling, and pain in inflammation.[10]
One of the initial events in the development of atherosclerosis is the accumulation of cells
containing excess lipids within the arterial wall. In addition, it has been demonstrated that
increased intracellular generation of reactive oxygen species (ROS) plays an important role in
chronic inflammatory responses to atherosclerosis. ROS are generated in aerobic organisms
during physiological or physiopathological oxidative metabolism of mitochondria. ROS may
react with a variety of biomolecules, including lipids, carbohydrates, proteins, nucleic acids, and
macromolecules of connective tissue, there by interfering with cell function. Under normal
physiological conditions, there is a critical balance in the generation of oxygen free radicals and
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antioxidant defense systems. Impairment in the oxidant/antioxidant equilibrium provokes a
situation of oxidative stress and generally results from hyperproduction of ROS. Oxidative stress
is known to be a component of molecular and cellular tissue damage mechanisms in a wide
spectrum of human diseases. A lot of oxygenated compounds, particularly aldehydes such as
malondialdehyde (MDA) and conjugated dienes, are produced during the attack of free radicals
to membrane lipoproteins and polyunsaturated fatty acids. A lot of studies have found that serum
MDA are higher in subjects with hyperlipidemia and decrease following dietary supplementation
with antioxidants. Similar observations have been reported in animal models of
hyperlipidemia.[11]
Lipid peroxidation is a fundamental process in CVD.[12] Currently it is believed that
oxidative stress modifies LDL and generates a negatively charged LDL that is supposed to be
recognized by macrophage scavenger receptors, leading to lipid accumulation. Conversely OxHDL becomes ineffective in removing cholesterol from foam cell macrophages.[13] The
important role of free radical oxidation of cellular components in CVD has been recognized
since the proposal of the oxidative theory of atherogenesis. Lipids are susceptible targets of
oxidation because of their molecular structure abundant with reactive double bonds.[14]

7

Fig.1. Process of lipid peroxidation[15]

Initially, a free radical takes a hydrogen atom from a poly unsaturated fatty acid. This
initial free radical is most likely a lipid hydroperoxide or hydrogen peroxide. The PUFA, now a
carbon-centered radical, reacts with oxygen to form a lipid peroxyl radical. This lipid peroxyl
radical takes a hydrogen atom from a nearby PUFA, making a lipid hydroperoxide and another
PUFA radical, thus continuing the cycle. These lipid hydroperoxides then decompose into
aldehydes, hydrocarbon gases, epoxides, ketones, and alcohols with the help of transition metal
ions. The aldehydes that are formed play an important role in oxidizing lipids.[16]
Ketones have been shown to be elevated in humans consuming high-fat diets. Alteration
in diet stimulates lipolysis and production of ketone bodies, including 3-hydroxybutyrate which
is most abundant in serum and urine.[17] When the accumulation of cholesterol and
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phospholipids accelerates, the proportion of ketone bodies incorporated into these lipids
increases.[18]
Ketone bodies are produced in the mitochondria of liver cells from acetyl-CoA derived
from oxidation of fatty acids, particularly under conditions where high concentration of free fatty
acids prevail.[19]

Fig. 2. Major ketone bodies structures[15]

Fig. 3. Major ketone bodies production

Derangements of ketone body metabolism occur in numerous disease states, including
types 1 and 2 diabetes and heart failure, and ketone body metabolism changes over the course of
normal aging. Studies suggest a therapeutic role for antioxidants in protecting from oxidative
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damage by ROS in the higher lipid period of the disease. Thus, in subjects with high risk for
developing hyperlipidemia, treatment with antioxidants might reduce the peroxidation rate,
restore the body’s antioxidant capacity, and possibly prevent or delay development of this
disease.[11]

1.1.4 Inflammation:
While the importance of inflammation in illnesses where the phenomenon is overt, such
as following trauma or infection has been recognized since ancient times, its presence and crucial
role in the manifestation of many diseases never previously recognized as inflammatory is
relatively recent. In such instances, the source of the inflammation is also often imperceptible.
This is especially relevant to the many pervasive chronic diseases that are still responsible for so
much human suffering. We are currently achieving a major understanding of what is involved in
the initiation of the inflammatory signaling cascade as well as the complex signaling pathways
themselves that transcribe and counterregulate the molecular messengers (cytokines) that
generate the biological combatants such as the inflammatory enzymes associated with the
numerous relevant pathologies.[10]
Inflammation has been suggested to be a key mediator of many events during
atherosclerosis development. [13] Inflammation resulting from oxidative stress is the cause of
much human disease. [10] CVD can generally be viewed as a form of chronic inflammation that
is induced and perturbed by lipid accumulation.[11] Proinflammatory cytokines are also involved
in cardiac muscle dysfunction and in the complex syndrome of heart failure.[10] Inflammation
has been suggested to be a key mediator of many events during atherosclerosis development.[13]
It is widely accepted that the earliest stages of the development of CVD are mediated, in large
part, by the inflammatory cascade. Expression of adhesion molecules increases recruitment of
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monocytes and T-cells to sites of endothelial injury magnifying the inflammatory cascade by
recruiting additional leukocytes, activating leukocytes in the media, and causing recruitment and
proliferation of smooth muscle cells. In response to signals generated within the early plaque,
monocytes adhere to the endothelium and then migrate through the endothelium and basement
membrane by elaborating enzymes that degrade the connective tissue matrix. Recruited
macrophages both release additional cytokines and begin to migrate through the endothelial
surface into media of the vessel. This process is further enhanced by the local release of
stimulating factors, which causes monocytic proliferation. Local activation of monocytes leads to
both cytokine-mediated progression of atherosclerosis, and oxidation of low-density lipoprotein.
Once initiated, many mediators of inflammation have been described to influence the
development of the atherosclerotic plaque. Inflammatory mediators expressed by smooth cells
within the atherosclerotic plaque include, but are not limited to, interleukin (IL)-1β, tumor
necrosis factor (TNF)α and β, IL-6, M-CSF, MCP-1, IL-18 and CD-40L. The impact of these
mediators is diverse and includes mitogenesis, intracellular matrix proliferation, angiogenesis
and foam cell development.[4]

1.1.5 Age:
The risk for CVD increases with age suggesting age-dependent mechanistic
components.[20] CVD is classed as a disease of aging as increasing evidence indicates that aging
is also an important risk factor and persists as an independent contributor when all other known
factors are controlled.[21] Interestingly, the level of oxidative stress increases during aging and
could be either due to increased production of reactive oxygen species (ROS) or reduced ability
to scavenge them. Increased oxidative stress can cause damage to cellular structures and can
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oxidize LDL to form atherogenic oxLDL, but it also can lead to dysregulation of signal
transduction and gene expression.[20]
Premature or accelerated vascular aging can be promoted by cardiovascular risk factors.
Vessel aging, even in the absence of atherosclerosis, leads to intimal and medial thickening as
well as gradual loss of arterial elasticity, resulting in vascular stiffness. Aged vessels show a
number of characteristic pathological processes, many of which are also seen in atherosclerosis.
Aged vessels show alterations in matrix and cell composition, elevated expression of a number of

proinflammatory molecules and increased uptake of plasma lipoproteins. These effects may be
due to increased expression of leukocyte adhesion molecules on endothelial cells in aged vessels,
which trigger the familiar processes of monocyte migration followed by increased uptake of
atherogenic lipo-proteins with subsequent inflammation, key events that ultimately promote
atherosclerosis. Aged ECs and vascular smooth muscle cells also show increased secretion of
proinflammatory cytokines, resulting in persistent vascular inflammation. Thus, the effects of
atherosclerosis are superimposed on normal aging of the underlying vessel.[21] Since ageassociated atherosclerosis correlates with lower expression of antioxidant genes, restoring their
expression and activity by curcumin or other phytochemicals or micronutrients could be a
strategy to increase stress resistance in vascular cells of the elderly.[20]
Treatment for atherosclerosis includes medical therapy, the mechanical reversal of
arterial stenosis, or artery bypass graft surgery. [6] Currently, statins that were first discovered as
a natural metabolite in Aspergillus terreus are the most widely prescribed drug to lower plasma
cholesterol levels. However, there is widespread interest in establishing alternative nonpharmacological ways to manage cholesterol based on natural dietary compounds, which may
prove to be more effective for reducing CVD risk. [22]
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1.2 CURCUMIN
Diet plays an important role in modulating the level of oxidative stress, as certain
components of diet (e.g., high glucose, fructose, and fat) have been associated with increased
levels of ROS, whereas antioxidants can chemically neutralize and prevent their damages. Free
fatty acids increase lipid-mediated oxidative and endoplasmic reticulum (ER) stress by various
mechanisms. On the other hand, reducing the amount of food intake by, for example, caloric
restriction has been linked to a lower level of oxidative stress and to an increased maximum
lifespan. Thus, the composition, quantity, and quality of diet are all important for regulating the
level of oxidative stress.[20]
Despite considerable efforts, the prevalences of complex multigenic human diseases such
as cardiovascular diseases, metabolic diseases, cancer, and neurological diseases have not
decreased significantly in recent years. A number of mono targeted drugs have emerged over the
past decade; however, the aforementioned diseases are caused by perturbations of multiple
signaling pathways. Thus, attacking only one of these multiple pathways is highly unlikely to be
effective. In addition, such monotargeted drugs are often very expensive and can produce
numerous adverse effects. These features of monotargeted drugs underscore the importance of
multitargeted, inexpensive, and readily available dietary agents or nutraceuticals for the
prevention and treatment of human diseases.
Curcumin is one such widely studied nutraceutical that was first purified about two
centuries ago by Harvard College laboratory scientists Vogel and Pelletier from the rhizomes of
Curcuma longa (turmeric).[23]
The therapeutic benefits of dietary constituents of plant origin have been the focus of
many extensive studies. Curcumin is a pigment obtained from the rhizomes of Curcuma
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longa.[24] The plant has a rhizome of bright orange color under a fine light brown cell layer. It is
in common use as a spice in Asian cultures, where it is considered to be a magical plant because
of its organoleptic properties and undoubted therapeutic and protective effects, especially for the
skin and liver. Since ancient times, many properties have been ascribed to extracts of Curcuma
longa.[12] Curcumin is also commonly used as a spice and a food-coloring agent.[24] The plant
has been applied for the prevention and cure of skin and hepatic conditions and of ulcers and
digestive disorders. It has also been used in the treatment of intestinal parasites and as a remedy
for poisoning, snakebites, and various other complaints. [12]

Fig.4.Chemical structure of curcumin[1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione].[25]

Curcumin is a highly pleiotropic molecule that was first shown to exhibit antibacterial
activity in 1949. Since then, this polyphenol has been shown to possess anti-inflammatory,
hypoglycemic, antioxidant, wound-healing, and antimicrobial activities. Extensive preclinical
studies over the past three decades have indicated curcumin’s therapeutic potential against a
wide range of human diseases. In addition, curcumin has been shown to directly interact with
numerous signaling molecules.[23]
In addition to a direct chemical action, recent studies suggest that phytochemicals and
micronutrient can also prevent oxidative stress by influencing signal transduction and gene
expression in non-antioxidant manners, for example by reducing the expression of enzymes
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producing free radicals, by inducing the expression of enzymes scavenging free radicals or
possibly as a secondary effect by influencing glucose and lipid homeostasis and thus reducing
systemic glucose and lipid mediated oxidative and ER stress.[20] For diabetes, a limited number
of studies indicate that curcumin is hypoglycemic and improves glucose tolerance. In a mouse
model of diabetes, curcumin increased the expression of FOXO1/FOXO3a in white adipose
tissue.[20] The capacity of curcumin to stabilize membranes has also been demonstrated.[12]

Fig.5 Possible sites of attack of free radical oxidants with curcumin[26]

Curcumin has been found to be an excellent scavenger of most ROS, a property that
bestows curcumin with antioxidant activity in normal cells. ROS consists of both free radical
oxidants and molecular oxidants. Free radical oxidants participate in hydrogen abstraction and
also in electron transfer reactions. All three active sites of curcumin can undergo oxidation by
electron transfer and hydrogen abstraction. Detailed investigations by different groups have
confirmed that during free radical reactions, the most easily abstractable hydrogen from
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curcumin is from the phenol-OH group, resulting in formation of phenoxyl radicals, which are
resonance stabilized across the keto-enol structure.[26]
Diet-induced hyper-cholesterolemia has long been useful for the assessment of agents
interfering with the absorption, degradation and excretion of cholesterol, rather than interfering
with choles-terol biosynthesis. Indeed, many animal species have been used in experiments to
evaluate the hypercholesterolemic effect of high-cholesterol diet, including rabbits, normal rats,
diabetic rats, diabetic and non-diabetic hamsters, Guinea pigs, and monkeys. [24]
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1.3 HYPOTHESIS
In this study we have hypothesised that curcumin would help in attenuating the affects of
atherogenic diet in aged rats. This hypothesis was tested using the following specific aims:
Specific aim 1A
To determine the effects of curcumin on the lipid profiles in aged rats fed an atherogenic diet
( 2% cholesterol and 2% cholesterol+ 2% curcumin)
Specific aim 1B
To evaluate effect of curcumin on HDL levels through gene expression analysis in aged rats fed
an atherogenic diet ( 2% cholesterol and 2% cholesterol+ 2% curcumin)
Specific aim 2A
To investigate effects of curcumin on lipid peroxidation in aged rats fed an atherogenic diet ( 2%
cholesterol and 2% cholesterol+ 2% curcumin)
Specific aim 2B
To determine the effects of curcumin on inflammatory response in aged rats fed an atherogenic
diet ( 2% cholesterol and 2% cholesterol+ 2% curcumin)
We assessed the possible hypolipidemic and antiatherogenic effect of the active
component of turmeric, curcumin, in male norway brown rats fed a high cholesterol diet. The
lipid profile was assesed as the major marker of hypercholesterolemia. Accordingly, total
cholesterol(TC), and high-density lipoprotein-cholesterol (HDL-C), Non- HDL, TC/HDL Ratio
were among the parameters investigated. To evaluate the effects of curcumin on lipid oxidation
MDA as TBARS and 3 Hydroxybutyrate were quantified while IL-6 was measured to evaluate
its effect on the inflammatory response.
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CHAPTER 2: Materials and Methods
2.1 Animals
24 in-bred Brown Norway (BN) rats were obtained from the aged rodent colonies of the
National Institute of Aging (Bethesda, MD). Upon arrival, 12 rats were 22 weeks old and 12 rats
are 24 weeks old.

2.2 Housing and husbandry
All animals were housed in individual cage at Wayne State University Division of
Laboratory Animal Resources (DLAR) facility under standard conditions as approved by the
Wayne State University Animal Investigation Committee (AIC). All of them were kept in the
same room with alternating 12 hours light alternating with 12 hours darkness under normal
humidity and at room temperature. Cage bedding and water were replaced weekly and their
health were monitored regularly.

2.3 Experimental protocol and diets
Upon arrival at the facility, all animals were allowed to acclimatize for one week prior to
start of the experiment. Following acclimatization period, they were assigned into 3 groups on a
random basis with the constraint that all diet groups had the same mean body weight. The groups
were named by their diets: Control Diet (C) (n = 8), High Cholesterol Diet (H) (n=8), and High
Cholesterol with Curcumin Diet (HC) (n=8). The diet compositions are summarized in Table 1.
Diets for all the groups were isocaloric. The purified diets were obtained in pellets from Dyets
Inc. (Bethlehem, PA), and sufficient diet was obtained for the entire duration of the study. The
diets were kept at -20°C, and diet was taken weekly as needed and kept refrigerated at 4°C.
Animals were fed ad libitum and had free access to tap water.
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Ingredient

Isocaloric Control High Cholesterol (2% Cholesterol) High Cholesterol + 2% Curcumin

Casein

140

140

140

L-Cystine

1.8

1.8

1.8

Sucrose

100

77.5

77.5

465.692

465.692

445.692

Dyetrose

155

155

155

Soyabean oil

40

40

40

0.008

0.008

0.008

Cellulose

50

50

50

Mineral Mix#210050

35

35

35

Vitamin Mix#310025

10

10

10

Choline Bitartrate

2.5

2.5

2.5

Cholesterol

_

20

20

Cholic Acid

_

2.5

2.5

Curcumin

_

_

20

Total

1000

1000

1000

Calorie

3602

Cornstarch

t-butylhydroquinone

3512
Table 1: Composition of purified diets (G/kg)

3440

2.4 Experimental Procedures
Experimental procedures carried out for this study as summarized in Table 2. All mice
were provided with their respective diets for 23 weeks and had free access to water. Body weight
and food intake were recorded twice a week throughout the duration of the study. Urine was
collected once a month for urinary metabolomic profiling. Upon completion of the experiment at
Week 23, each animal was anesthetized using carbon dioxide chamber and decapitated followed
by exsanguination and tissue collection. Tissues were flash-frozen in liquid nitrogen then stored
at -80ºC until ready to be used for analysis. All procedures and protocols were in accordance
with and ratified by the Animal Investigation Committee of Wayne State University.
Procedures
Frequency of Measurement
Body weight, diet intake, water intake
Twice weekly (Week 1-6)
Urine collection
Once weekly (Week 2,4,6)
Blood and tissue collection
End of study (Week 6)
Table 2: Study timeline based on the overall study
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2.5 Plasma Total Cholesterol
Total cholesterol (TC) cholesterol were determined using enzymatic kits (TC; Pointe
Scientific Inc. Canton, MI.). Plasma was isolated by centrifugation of blood at 4000 rpm for 20
minutes at 4°C and stored in -80ºC until use. Samples and standards were taken and the test tubes
were labeled accordingly. 1ml of reagent was pipetted into each tube and pre-warmed at 37°C for
five minutes. 10µL of sample was added into respective tubes, mixed and returned to 37°C for
incubation for five minutes. Spectrophotometer was zeroed with blank at 500nm and
absorbances of all test tubes were recorded. The concentration of unknown samples was
calculated by using standard curve.

2.6 Liver Total Cholesterol
2.6.1 Folch Assay
Folch method [27] was used to extract lipids from liver tissues. 0.5g of liver tissue was
taken and homogenized in 10mL chloroform-methanol solution 2:1(v/v). The samples were left
overnight in a shaking water bath. 3mL of 0.5% H2SO4 was added for separating the phases.
The lower phase was taken and the volume was brought to 10ml by addition of chloroformmethanol mixture. Aliquots of 50µL were made and dried overnight. Reconstituted the aliquots
with 50µL EtOH.

2.6.2 TC Assay
TC was determined using enzymatic kit and same protocol as plasma was followed.

2.7 HDL Plasma
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Extracted plasma from -80 ºC was used. Liver lipids were extracted using Folch’s method
described above.

2.7.1 Separation of HDL Cholesterol:
Samples were taken and the test tubes were labeled accordingly. 0.5 ml (500µL) sample
was pipetted into the respective tubes and 0.5 ml (500µL) reagent was added into each tube and
mixed using vortex. The tubes were centrifuged at 2000g for 10 minutes.

2.7.2 HDL Cholesterol Determination:
Samples and standards were taken and the test tubes were labeled accordingly. 1ml
enzymatic cholesterol reagent, which was prepared according to package insert instructions, was
pipetted into each tube. Then 0.05 ml (50µL) standard or clear supernatants from above step
were pipetted into their respective tubes. All tubes were incubated for 10 minutes at 37°C. The
spectrophotometer was zeroed at 500nm with reagent blank and absorbance’s of all test tubes
were recorded. The concentration of unknown samples was calculated by using standard curve.

2.8 PCR- ApoA1
2.8.1 RNA Extraction
Liver tissue samples were taken from each group for gene expression analysis. The total
RNA extraction assay was performed using commercial kit (RNeasy Mini Kit, Qiagen Valencia,
CA) following the manufacturer’s instructions. Tissue samples from liquid nitrogen were taken
and approximately 30mg of frozen liver tissue was excised, weighed and then placed into 700µL
QIAzol Lysis Reagent in a vessel which is suitable for disruption and homogenization using
tissue homogenizer. The tube which contains the homogenate was then placed at room
temperature (15-25˚C) for 5 minutes. Added 140µL of chloroform to the tube, capped securely
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and the tube was shaken vigorous for 15 seconds. The tube was kept at room temperature for 3
minutes followed by centrifugation for 15 minutes at 12,000rcf at 4˚C. After centrifugation, the
upper aqueous phase was transferred to a new collection tube. Then 525µL of 100% ethanol was
added to the tube and mixed thoroughly by pipetting. Next, 700µL of sample including any
precipitate was pipetted into RNeasy Mini spin column in 2 ml collection tube and centrifuged at
10,000 rpm for 15 seconds. Discarded the flow-through and the same step as above was repeated
for the remainder of sample. Added 700µL of Buffer RWT to RNeasy Mini spin column,
centrifuged at 10,000 rpm for 15 seconds and flow-through was discarded. 500µL of Buffer RPE
was then pipetted onto RNeasy Mini spin column and again and centrifuged at 10,000 rpm for 15
seconds. The flow-through was discarded and 500µL of Buffer RPE was added to RNeasy Mini
column and then centrifuged at 10,000 rpm for 2 minutes. RNeasy Mini spin column was then
places into a new 2 ml collection tube and centrifuged at full speed for 1 minute. The RNeasy
Mini spin column was transferred to a new 1.5 ml collection tube after the old collection tube
was discarded with the flow through. 40µL of RNase-free water was then pipetted directly on the
RNeasy Mini spin column membrane and centrifuged for 1 minute at 10,000 rpm to elute the
RNA. Then using the Nanodrop spectrophotometer quantity measurement and the
spectrophotometric quality assessment (A260/280 and A260/230 ratios) of RNA were carried
out.

2.8.2 cDNA Preparation
Reverse transcription of the liver RNA was performed using High Capacity RNA to
cDNA Master Mix kit (Applied Biosystems, Carlsbad, CA). 20 µL of RT buffer mix, 2µL of RT
enzyme mix, 8µL of RNA sample and 10µL of nuclease-free water were taken and mixed into
0.2mL PCR tube and centrifuged for few seconds. The prepared samples were then loaded into
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Eppendorf mastercycler realplex 4 (Eppendorf, Hauppauge, NY) for reverse transcription
process with the following temperature setting; 25˚C for 5 minutes, 42˚C for 30 minutes, 85˚C
for 5 minutes and was then transferred to a -20˚C freezer until use for qRT-PCR analysis.

2.8.3 Quantitative Real-Time Polymerase Chain Reaction (qPCR)
qPCR was performed as part of gene expression analysis. ApoA1 gene which encodes
apolipoprotein A-I, the major protein component of HDL was tested in liver samples. The primer
sequence of the gene is listed in Table 2. The final reaction volume of 25 uL was made using
12.5µL SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), 1µL of 20 µM
reverse and forward primer mixture, 9.5µL nuclease-free water and 2µL of cDNA. qRT-PCR
was carried out on the Eppendorf mastercycler realplex 4 instrument (Eppendorf, Hauppauge,
NY) in Mx3000P 96-Well Plates (Agilent Technologies) with the following settings; initial
denaturation: 95˚C for 10 minutes, 45 repetitions of denaturation: 95˚C for 15 seconds and
elongation: 60˚C for 1 minute, dissociation curve: 95˚C for 1 minute, 60˚C for 30 seconds
followed by gradual temperature increase from 60˚C to 95˚C in 20 minutes and finally at 95˚C
for 30 seconds. Each gene was analyzed in triplicate with single NTC. mRNA expression levels
in the samples were calculated relative to Control, High cholesterol diet and High cholesterol
with curcumin diet using the comparative CT method: ∆∆CT = ∆CT sample - ∆CT control,
fold change = 2-∆∆CT. GAPDH was used to normalize the expression values (∆CT).
Primer’s Name
ApoA1

Forward Sequence
Reverse Sequence
5′- AGGAGCAGACCCAGCAGATA- 3′
5′- AACCCAGAGTGTCCCAGTTG-3′
Table 3: Primer sequence of the ApoA1 gene

2.8.4 Data Analysis
A fold change cut-off of more than 2 was used in determining any significant change of
gene expression relative to control
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2.9 Liver TBARS
2.9.1 Liver tissue homogenization
25mg of tissue was weighed and transferred into a tube. 250µL of RIPA buffer
containing protease inhibitor was added to the tube. The tissue was sonicated on ice for 15
seconds and vial tube was centrifuged at 1600×g for 10 minutes at 4ºC. The supernatant was
stored at -80ºC until used for analysis.

2.9.2 BCA Protein Quantification
Pierce BCA Protein Assay Kit was purchased from Thermo Fisher Scientific Inc. Grand
Island, NY. The standards and working reagents were prepared according to manufacturer’s
protocol. 25µL of each standard or unknown sample replicates were pipetted into a microplate
well. 200µL of the WR added to each well and mixed the plate thoroughly on a plate shaker for
30 seconds. The plate was covered and incubated at 37°C for 30 minutes. Cooled the plate to RT
and measured the absorbance at 562nm on a plate reader.

2.9.3 TBARS Assay
TCA TBARS Assay kit was purchased from Cayman Chemical Ann Arbor, Michigan.
All the reagents were brought to room temperature before starting the assay. The standards and
samples were prepared according to manufacturer’s instructions and the vials were labeled
accordingly. 100µL of sample or standard was taken into the vial and 100µL of TCA Assay
Reagent was added to each vial. Then 800µL of color reagent was added to each vial and
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vortexed. The vials were capped and placed in foam holder to keep the vials upright during
boiling. The vials were then added to vigorously boiling water and left for an hour. After one
hour the vials were taken and placed in ice bath immediately to stop the reaction and incubated
on ice for 10 minutes. The vials were then centrifuged for 10 minutes at 1600×g at 4°C. 200µL
from each vial was taken and transferred to assigned slots in plate an absorbance was read at
540nm. The concentration of unknown samples was calculated by using standard curve. The
samples were normalized using BCA protein quantification.

2.10 Plasma TBARS
Stored plasma from -80°C and thawed on ice. Plasma TBARS was performed by using
the same method as liver tissues following the manufacturers protocol.

2.11 Urine 3-Hydroxybutyrate
2.11.1 Creatinine Quantification
The Colorimetric Assay kit was purchased from Cayman Chemical Ann Arbor,
Michigan. Stored urine samples from -80°C were taken and thawed on ice. Urine was diluted 1:5
with assay buffer and the standards, and reagents were prepared, according to manufacturer
instructions. 15µL of samples and standards are added to the wells. The reactions were initiated
by adding 150µL of alkaline pictrate solution to each well. The plate was covered and incubated
at room temperature for 10 minutes. The initial absorbance was measured at 500nm after
removing the cover. Then 5µL of acid solution was added to each well and the plate was covered
followed by incubation for 20 minutes at room temperature on a shaker. The cover was removed
and the final absorbance was read at 500nm. The average final absorbance was subtracted from
the average initial absorbance to get the corrected absorbance. The corrected absorbance of
standard A was subtracted from itself and all other standards and samples to get adjusted

25

absorbance. This adjusted absorbance of standards was plotted on standard curve to obtain the
concentration of creatinine of unknown samples.

2.11.2 3-hydroxybutyrate Assay
Urine samples were used for measuring the ketone body 3-hydroxybutyrate. The
Colorimetric Assay kit was purchased from Cayman Chemical Ann Arbor, Michigan. Stored
urine samples from -80°C were taken and thawed on ice. Urine was diluted 1:5 with assay buffer
and the standards, and reagents were prepared, according to manufacturer instructions. 50µL of
standards and samples were added to the wells in triplicates. The reaction was initiated by adding
50µL of developer solution to each well. The plate was incubated in dark at 25°C for 30 minutes.
The absorbance was read at 455nm and the values were recorded. The concentration of unknown
samples was calculated by using standard curve. The urine samples were normalized using
creatinine.

2.12 IL-6 ELISA
IL-6 ELISA Immunoassay kit was purchased from R&D Systems Inc. Minneapolis, MN.
All the reagents, standard dilutions, control, and samples were reconstituted according to
manufacturer’s protocol. Plasma was taken from -80 ºC and thawed on ice. 50 μL of Assay
Diluent RD1-54 was added into each well and then 50 μL of standards or samples were added
into their respective wells. The samples were mixed by gently tapping the plate frame for 1
minute. The plates was covered with the adhesive strip provided and incubate for 2 hours at
room temperature. Aspirated each well and washed, repeating the process four times for a total
of five washes. The wells were washed by filling each well with Wash Buffer (400 μL) using a
squirt bottle. Plate was inverted and blotted against clean paper towels. After this 100 μL of Rat
IL-6 Conjugate was added to each well and covered with a new adhesive strip. Incubated for 2
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hours at room temperature and repeated the aspiration/wash as explained above. Then 100 μL of
Substrate Solution to each well and incubated for 30 minutes at room temperature taking care it
is protected from light. After 30 minutes 100 μL of Stop Solution was added to each well and
gently tapped the plate to ensure thorough mixing. The optical density of each well was
determined within 30 minutes, using a microplate reader set to 450 nm. The concentration of
unknown samples was calculated by using standard curve.
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CHAPTER 3: Results

Body weight In grams

Body weight and food intake:
C

500.0
450.0
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300.0
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Fig. 6. Mean body weight of rat at week 1 and Week 23 is shown. Results represent mean + SE. Comparisons were
achieved using one way ANOVA followed by LSD as post-hoc test. No significant difference was between group in
week 1 and Week 23.
120
Diet Intake in grams

100
80

C

60

H

40

HC

20
0
Week 1

Endpoint

Fig. 7. Mean food intake of rats at week 1 and week 23 is shown. Results represent mean diet consumption.
Comparisons were achieved using one way ANOVA followed by LSD as post-hoc test. No significant difference
was between group in week 1 and Week 23.

Specific aim 1A
To determine the effects of curcumin on the lipid profiles in aged rats fed an atherogenic diet (
2% cholesterol and 2% cholesterol+ 2% curcumin)

Plasma Total Cholesterol:
The effects of curcumin on total cholesterol content of plasma has been shown in the
figure 8. The groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC)
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have been compared. TC was measured in C, H, and HC group’s rats using enzymatic assay kits.
Significant difference was observed between the groups.

300.0
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Fig. 8. Effect of curcumin on the Plasma TC in aged rats. Results represent mean + SE. Comparisons were achieved
using one way ANOVA followed by LSD as post-hoc test. a–H is significantly different from C, at p<0.05. b –H is
significantly different from HC at p<0.05. c- HC is significantly different from C.

Plasma High Density Cholesterol:
The effects of curcumin on HDL cholesterol content of plasma has been shown in the
figure 9. The groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC)
have been compared. HDL was measured in C, H, and HC group’s rats using enzymatic assay
kits. Significant difference was observed between the groups.
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Fig. 9. Effect of curcumin on the Plasma HDL in rats. Results represent mean + SE. Comparisons were achieved
using one way ANOVA followed by LSD as post-hoc test. a – H, Significantly different from C at p<0.05.
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Plasma Non-HDL:
The plasma Non-HDL cholesterol content has been shown in the figure 10. It is measured
as difference of TC and HDL. The groups Control (C), high cholesterol (H) and high cholesterol
with curcumin (HC) have been compared. Significant difference was observed between the
groups.
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Fig. 10. Effect of curcumin on the Plasma Non-HDL measured as TC-HDL in rats. Results represent mean + SE.
Comparisons were achieved using one way ANOVA followed by LSD as post-hoc test. a– H is significantly
different from C, at p<0.05. b –H is significantly different from HC at p<0.05. c- HC is significantly different from
C at p<0.05.

Plasma TC/HDL Ratio:
The effects of curcumin on TC/HDL cholesterol ratio of plasma has been shown in the
figure 11. The groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC)
have been compared. Significant difference was observed between the groups.
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Fig. 11. Effect of curcumin on the Plasma TC/HDL ratio in rats. Results represent mean + SE. Comparisons were
achieved using one way ANOVA followed by LSD as post-hoc test. a – H is significantly different from C, at
p<0.05. b –H is significantly different from HC at p<0.05. c- HC is significantly different from C at p<0.05.

Liver TC:
The effects of curcumin on total cholesterol of liver has been shown in the figure 12. The
groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC) have been
compared. TC was measured in C, H, and HC group’s rats using enzymatic assay kits.
Significant difference was observed between the groups.
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Fig. 12. Effect of curcumin on the liver TC in rats. Results represent mean + SE. Comparisons were achieved using
one way ANOVA followed by LSD as post-hoc test. a – H, Significantly different from C at p<0.05. b –H,
Significantly different from HC at p<0.05.

Specific aim 1B
To evaluate effect of curcumin on HDL levels through gene expression analysis in aged
rats fed an atherogenic diet ( 2% cholesterol and 2% cholesterol+ 2% curcumin)
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RT-PCR:
The effects of curcumin on gene expression of liver has been shown in the figure 14. The
groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC) have been
compared PCR was done in C, H and HC group’s rats using kits. Significant difference was
observed between the groups.
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Fig. 14. Effect of curcumin on the mRNA expression of ApoA1 in rat liver. The expression is presented as fold
change with respect to KC. a is significantly different from b.

Specific aim 2A
To investigate effects of curcumin on lipid peroxidation in aged rats fed an atherogenic diet ( 2%
cholesterol and 2% cholesterol+ 2% curcumin)

Liver TBARS:
The effects of curcumin on lipid peroxidation of liver has been shown in the figure 15.
The groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC) have been
compared. TBARS was performed in C, H, and HC group’s rats using kits. Values are expressed
per mg of protein. Significant difference was observed between the groups.

TBARS nmol/mg Protein
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Fig. 15. Effect of curcumin on the the lipid peroxidation in rat liver. Results represent mean + SE. Comparisons
were achieved using one way ANOVA followed by LSD as post-hoc test. a – H is significantly different from C, at
p<0.05. b –H is significantly different from HC at p<0.05. c- HC is significantly different from C at p<0.05.

Plasma TBARS:
The effects of curcumin on lipid peroxiation of plasma has been shown in the figure 16.
The groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC) have been
compared. TBARS was perofromed in C, H, and HC group’s rats using kits.
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Fig. 16. Effect of curcumin on the lipid peroxidation in rat Plasma. Results represent mean + SE. Comparisons were
achieved using one way ANOVA followed by LSD as post-hoc test. b– H is significantly different from C at p<0.05.
b –H is significantly different from HC at p<0.05.

Urine 3-hydroxybutyrate:
The effects of curcumin on ketone body production through oxidation of fatty acids has
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been shown in the figure 17. The groups Control (C), high cholesterol (H) and high cholesterol
with curcumin (HC) have been compared. Assay was performed in C, H, and HC group’s rats
using kits. Values are represented per mg of creatinine. Significant difference was observed
between the groups.
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Fig. 17. Effect of curcumin on the urine 3-hydroxybutyrate levels in rats. Results represent mean + SE. Comparisons
were achieved using one way ANOVA followed by LSD as post-hoc test. a – H is significantly different from C, at
p<0.05. b –H is significantly different from HC at p<0.05. c- HC is significantly different from C at p<0.05.

Specific aim 2B
To determine the effects of curcumin on inflammatory response in aged rats fed an
atherogenic diet ( 2% cholesterol and 2% cholesterol+ 2% curcumin)

Interleukin-6:
The effects of curcumin on plasma inflammatory cytokine IL-6 has been shown in the
figure 18. The groups Control (C), high cholesterol (H) and high cholesterol with curcumin (HC)
have been compared. Assay was performed in C, H, and HC group’s rats using ELISA kit.
Values are represented per mg of creatinine. Significant difference was observed between the
groups.
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Fig. 18. Effect of curcumin on the Plasma IL-6 levels in rats. Results represent mean + SD. Comparisons were
achieved using one way ANOVA followed by LSD as post-hoc test. a – H, Significantly different from HC at
p<0.05.

Parameter

Plasma TC
Plasma HDL
Plasma TC/HDL
Plasma Non-HDL
Liver TC
Liver HDL
Plasma TBARS
Liver TBARS
Urine 3-Hydroxybutyrate
Plasma IL-6

C
a

117.2 ± 20.5

a

b

221.1 ± 35.5

1.9 ± 0.4

54.6 ± 21.4
a

HC
c

179.2 ± 23.0

b

62.6 ± 11.8
a

a

H

45.3 ± 9.6

53.5 ± 9.2

b

c

5.0 ± 1.3

b

175.8 ± 38.1

c

3.4 ± 0.7

125.7 ± 24.7

b

b

0.76 ± 0.2

0.44 ± 0.19

0.61 ± 0.3

a

b

a

1.8 ± 0.7

8.4 ± 2.26

5.96 ± 1.9

a

50.5 ±8.7

a

6.7 ± 1.8

9.7 ± 2.58

b

80.3 ± 19.15

3.2 ± 0.5

b

70.1 ± 8.3

a

10.8 ± 1.6

80.5 ± 9.6

a

4.1 ± 1.3

53.8 ± 8.17
c
b

4.4 ± 0.2

68.9 ± 6.4

Values are expressed as the means ± SE. Groups were compared by one-way analysis of variance, followed by LSD.
Table 4: Effect of curcumin on plasma and liver lipids, oxidation and inflammatory cytokines in aged Brown
Norway rats.
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CHAPTER 4: Discussion
Cardiovascular disease(CVD) is a leading cause of global mortality, accounting for
almost 17 million deaths annually.[28] For many years, it has been recognized prolonged
elevation of blood cholesterol levels, is an established cardiovascular disease risk factor in
humans.[29] Therefore, reduction of circulating TGs, TC and LDL-C, increasing HDL-C is a
primary step in the prevention of vascular disease.[28] The induction of hyperlipidemia, in
particular hypercholesterolemia, by feeding experimental animals a high cholesterol diet, has
been suggested by many scientists as a reliable model for CVD in humans.[24] Therefore, our
main objective in the current study was to induce hypercholesterolemia in rats after feeding the
animals a high cholesterol diet, which was earlier described by Fillios et al. as an atherogenic
diet. In this context, the plasma lipid profile, liver lipid profile, and some anti-oxidant and antiinflammatory parameters were investigated. Feeding rats with a high cholesterol diet for 23
consecutive weeks resulted in marked hypercholesterolemia, as the plasma total cholesterol (TC)
level was much greater than that of control animals. This is in accord with previous findings
reported by Beynen et al. , who showed that feeding four different strains of rats a diet
containing 2% cholesterol and 0.5% cholate for 13 days induced a pronounced
hypercholesterolemia. Also, Monte and Jimenez have demonstrated that feeding Wistar rats for
20 days a hypercholesterolemic diet increased the plasma cholesterol and hepatic content of total,
free and esterifi ed cholesterol. Similar results have been reported by Sakuma et al. following
one week feeding of a 1% cholesterol, 0.5% cholic acid diet to normal and diabetic rats.[24]
We addressed the possible hypolipidemic effects of curcumin. Curcumin is extracted
from Curcumae Longae, and it has been demonstrated that curcumin has a variety of
pharmacological effects, such as antitumoric, anti-inflammatory, as well as antioxidative
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effects.[30] The present study investigated curcumin's ability to reduce effects of atherogenic
diet in aged rats. Using this hypercholesterolemic rat model, we evaluated the lipid-lowering
effect of curcumin, and our results showed that rats fed a high cholesterol diet supplemented with
curcumin for 23 weeks had a reduced plasma TC, Non–HDL Cholesterol, TC/HDL Ratio, and
liver TC, and improved plasma HDL Cholesterol levels, which are sensitive biomarkers of
coronary heart disease, compared with rats fed a high cholesterol diet only. Increased plasma
HDL-C levels are widely reported to be associated with decreased risk of cardiovascular
disease.[22] These results are in agreement with studies by Yuan et al. [31] and Um et al. [29]
suggesting that curcumin consumption significantly decreased plasma lipid levels in animals.
Similar results have been observed by Hossam et al.[24] in rats fed high cholesterol diet. Soni
and Kuttan have shown a significant increase in serum HDL-C and a decrease in serum TC in
human volunteers ingesting turmeric spice, suggesting a protective role of curcumin in arterial
diseases. Similarly, Soudamini et al. have reported that oral administration of curcumin to mice
could significantly lower serum and tissue cholesterol levels. In rabbits with experimental
atherosclerosis, an ethanol extract of turmeric was found to induce a hypocholesterolemic effect.
Using an adriamycin-induced nephrotic hyperlipidemia model in rats, Venkatesan et al. proved
that curcumin had a lipid-lowering effect. Furthermore, Asai and Miyazawa have demonstrated
that dietary curcuminoids had lipid-lowering potency in rat liver and epididymal adipose tissues.
[24] Hasan et al. [32] also reported that curcumin administration has reduced the liver and
plasma lipids significantly in mice fed high fat diet.
ApolipoproteinAI (apoAI), a major component of the high-density lipoprotein (HDL)
particle, is necessary for the efficient transport and clearance of cholesterol from peripheral
tissues to the liver for metabolism and secretion through a process called reverse cholesterol
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transport. Epidemiologic studies suggest that low levels of this protein are associated with an
increased risk of heart disease.[33] We found the expression of the gene ApoA-1, which encodes
the apolioprotein A-I was significantly upregulated by curcumin. This is in accordance with the
study by shin et al.[22] in LDLR−/− mice fed a high-cholesterol diet.
Free radicals and associated reactive species have been implicated in atherosclerosis and
its complications. A cholesterol rich diet also induces free radical production, followed by
oxidative stress.[28] Oxidative stress represents a situation where there is an imbalance between
the reactive oxygen species (ROS) and the availability and the activity of antioxidants. This
balance is disturbed by increased generation of free radicals or decreased antioxidant activity.[9]
Lipids are very susceptible to attack by free radicals and oxidized LDL (Ox-LDL) species appear
to contribute to the atherosclerosis pathobiology. Hypercholesterolemia leads to increased
production of ROS which exert their cytotoxic effect by causing lipid peroxidation.[28]
Numerous studies have reported that dietary cholesterol consumption by animals elevates lipid
peroxidation, as measured by levels of a lipid oxidation marker thiobarbituric acid reactive
substances (TBARS).[28, 34] The TBARS assay has been applied as an indicator of oxidative
stress in a number of cardiovascular disease animal models.[14] TBARS levels were seen to be
strongly associated with cardiovascular risk factors, such as hyperlipidemia, cigarette smoking,
hypertension, and diabetes. [28, 34] TBARS concentrations are elevated in the plasma of rats,
which are streptozotocin induced diabetic models. TBARS were also increased in the serum of
cigarette smokers. A study of TBARS in 634 patients with documented coronary artery disease
found that serum levels of TBARS could predict major cardiovascular events and the need for a
major vascular procedure in a 3-year follow-up period independently of traditional risk factors
and inflammatory markers. Moreover, elevated TBARS levels predicted carotid atherosclerotic
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plaque progression over 3 years as assessed by carotid wall thickness on ultrasound. Animal and
human studies therefore support a potential role of lipid oxidation in predicting the progression
of CVD and response to therapies.[14] In our study curcumin administration the levels of
TBARS in plasma and liver were significantly lower in the HC and C groups when compared to
H group. This is in accordance with the study by Quiles et al.[12] who showed that
supplementation with Curcuma longa reduced levels of TBARS significantly in rabbits fed
atherogenic diet. Kuo et al. [35] also reported similar results in obese mice with hepatic steatosis
fed curcumin diet.
Studies have shown that fatty acid administration leads to elevated rates of fat
oxidation.[36] Alteration in diet stimulates lipolysis and production of ketone bodies, including
3-hydroxybutyrate which is most abundant in serum and urine.[17] When the accumulation of
cholesterol and phospholipids accelerates, the proportion of ketone bodies incorporated into
these lipids increases. 3-Hydroxybutyric acid (or beta-hydroxybutyrate) is a ketone body. Like
the other ketone bodies (acetoacetate and acetone), levels of 3-hydroxybutyrate in blood and
urine are raised in ketosis. In humans, 3-hydroxybutyrate is synthesized in the liver from acetylCoA, and can be used as an energy source by the brain when blood glucose is low. Diabetic
subjects who experience frequent episodes of hyperketonemia also experience increased
incidences of vascular disease, morbidity, and mortality. The mechanisms by which
hyperketonemia influences the development of vascular disease remains unknown.[18]
Cholesterol is an important biomarker of hyperlipidemia, and its level significantly decreased
after administering curcumin. Endogenous cholesterol synthesis by acetyl-CoA should be lower,
but the β-oxidation of fatty acids should be higher in the diet-induced hyperlipidemia rats
because of the feedback regulation during excessive lipid metabolism. These processes should

39

result in an accumulation of acetyl-CoA in vivo. The excess of acetyl-CoA may have been
converted to acetone bodies, as indicated by the high level of β-hydroxybutyric acid in the high
cholesterol group.[37] Previous studies have reported increased production of ketone body 3hydroxybutyrate in hyperlipidemic animal models.[38] In our study significant difference was
observed between the groups following treatment. The lipid-lowering effect of curcumin might
have led to a decrease in the β-hydroxybutyric acid level in the urine following its
administration. This is accordance with another study by Li et al. [39] who showed that curcumin
administration significantly reduced ketone body levels in mice fed high fat diet. In conclusion,
supplementation with Curcuma longa extract reduces oxidative stress and attenuates the
development of CVD events in rats fed a high cholesterol diet.[12]
Inflammation is another important contributor to CVD, as cytokines amplify the local
inflammatory response and promote the progression of atherosclerotic lesions.[29] Interleukin-6
(IL-6), a circulating cytokine, has been identified as a marker of inflammation in coronary
atherosclerotic plaques.[40] In previous studies the levels of TBARS measured in CVD patients
also correlated directly with levels of the proinflammatory cytokine, IL-6. Production of IL-6
from vascular cells is triggered by the proatherogenic factor, angiotensin II, which also
stimulates reactive oxygenspecies involved in lipid oxidation. Cytokine production from smooth
muscle cells is also stimulated directly by oxidized lipids. The correlation between levels of this
cytokine and TBARS results from common early events in atherogenesis.

[34] IL-6 also

regulates the expression of other inflammatory cytokines, such as interleukin-1 (IL-1) and tumor
necrosis factor-α (TNF- α). [40] In addition, previous in vitro and animal studies indicate that
curcumin has widespread anti-inflammatory effects. Therefore, attenuation of inflammatory
cytokines may contribute to the decreased inflammatory response in rats receiving curcumin
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supplementation.[29] For this reason, we investigated whether curcumin prevents CVD risk by
reducing cytokine levels. In high cholesterol + curcumin fed rats, our results showed that
curcumin reduced plasma levels of IL-6. This is in accordance with another study by Singh and
Vinayak [41] suggesting that curcumin administration significantly decreased IL-6 levels in rats
skin. Also Um et al. [29] have shown similar results in rabbits fed high cholesterol diet. Similar
results have been reported by Belcaro et al. [42] in serum of human patients with diabetes when
treated with a curcumin for 8 months. Usharani et al. [43] have shown that IL-6 levels were
reduced in human osteoarthritis patients when treated with a curcumin supplementation for 8
weeks. Also Hasan et al.[32] reported similar results in plasma of mice fed high fat diet with
curcumin supplementation when compared to control group.
Cholesterol levels in the body result from two sources: absorption from the
gastrointestinal tract and endogenous de novo synthesis.[24] The hypolipidemic effect of
curcumin observed in the current study could possibly be ascribed to an effect on the absorption
of cholesterol in the gut, especially curcumin was admixed with the HCD. Many previous reports
could lend support to this view. Ammon and Wahl[44] have reported that after oral
administration only traces of curcumin were found in the blood, and that most of the curcumin
was excreted via feces, indicating poor absorption of curcumin from the gut. Another plausible
explanation for the hypolipidemic effect of curcumin, though speculative at present, is that it
may have increased the rate of cholesterol catabolism by increasing the activity of hepatic
cholesterol 7-a-hydroxylase enzyme. This enzyme is the rate-limiting enzyme of bile acid
biosynthesis, thus suggesting that curcumin could stimulate the conversion of cholesterol to bile
acids, an important pathway of elimination of cholesterol from the body as reported by Kim et
al..[2]
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Curcumin has two o-methoxy phenolic OH groups attached to the β-diketone moiety
having methylene CH2 group. It is believed that the H abstraction from these groups are
responsible for the remarkable antioxidant activity of curcumin. Some methods attributed the H
abstraction from the methylene CH2 group but others attributed to the phenolic OH groups. It has
been illustrated the mechanism of probable two sites of free radical reaction with curcumin to
produce a phenoxyl radicals or at the methylene CH2 group to produce the carbon-centered
radical. These radicals are resonance stabilized and can be interconverted through the
conjugation.[45]

ROS

Aldehydes
Ketones

↓ Hyperlipidemia

Curcumin

↓ Oxidation

↓ Plasma TBARS
↓ Plasma TC
↓ Liver TBARS
↑ Plasma HDL
↓ Plasma Non-HDL

↓ Cardiovascular
Disease Risk

↓ 3-Hydroxybutyrate

↓ Plasma TC/HDL

Cytokine
expression

↓ Liver TC
↑ Liver HDL
↑ ApoA1
↓ Inflammation

↓ Interleukin-6
Fig 19: Effect of Curcumin on atherogenic diet and reduced risk of CVD
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CHAPTER 5: Conclusion and future directions
In summary, these results support our hypothesis and indicate that curcumin may prevent
the progression of CVD events by reducing atherogenic diet effects in rat model. This beneficial
effect may be mediated by a reduction in plasma and liver TC, Non-HDL,TC/HDL levels,
oxidation and proinflammatory cytokine production, and increasing plasma and liver HDL
levels. These findings demonstrate the protective mechanisms of curcumin in an experimental
model of CVD and suggest its potential role in treating CVD. [29]
Measuring HDL particle size and functionality- Epidemiological studies have shown that low
plasma levels of high density lipoprotein cholesterol (HDL-C) represent a cardiovascular disease
(CVD) risk factor. HDL particles are very heterogeneous in terms of size, structure, composition
and metabolism. [46] HDL is comprised of number of particles of different size. It is believed
that lipid poor HDL partilcles are better acceptors than large HDL particles.[47] Additionally,
recent studies challenge the concept that an increase of plasma HDL-C will uniformly translate
into a reduction in CVD risk. Certain patients with atherosclerosis may have “dysfunctional”
HDL despite normal HDL-C levels.[46] Researchers have proposed that in some people HDL
was dysfunctional, or malformed, and unable to do its job properly. HDL particles have several
functions related to trafficking cholesterol and proteins. If HDL particles perform these biologic
tasks they are termed, “functional”. If they do not, they are termed “dysfunctional”. [48] These
characteristics may play divergent roles and result in different clinical outcomes. Hence, the
association of the structure of HDL particle with its functionality and metabolism should be
clarified and accordingly used in the clinical setting.[46]
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ABSTRACT
CURCUMIN ATTENUATES THE EFFECTS OF ATHEROGENIC DIET IN
AGED MALE BROWN NORWAY RATS
by
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Cardiovascular disease (CVD) is a universal problem in modern society. Hyperlipidemia
is a major risk factor for the development of cardiovascular disease. Hyperlipidemia further leads
to increased oxidation and inflammation. Curcumin has long been used as a spice and foodcoloring agent. In experimental animals, curcumin has shown anti-diabetic, anti-inflammatory,
cytotoxic and anti-oxidant properties. In this study, Aged Brown Norway Rats were fed 1 of 3
experimental diets: a normal control diet (C), a normal diet enriched with 2%cholesterol (H), or a
High Cholesterol Diet supplemented with 2% curcumin. Feeding the animals a high cholesterol
diet for 23 weeks resulted in marked hypercholesterolemia, increased Plasma Total Cholesterol
(TC), but decreased plasma high-density lipoprotein cholesterol (HDL). Curcumin admixed with
the diet significantly decreased plasma and liver total cholesterol (TC) and increased HDL. The
atherogenic indices TC/HDL was significantly reduced. Curcumin also decreased the mRNA
expression of ApoA1 gene, oxidative and inflammatory responses which were increased in High
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cholesterol group. Our results demonstrate that curcumin improved CVD risk by lowering
detrimental plasma total cholesterol, Non- HDL cholesterol, TC/HDL, and increasing beneficial
HDL cholesterol, possibly by modulating the oxidation and proinflammatory biochemical
pathways.
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